AAPG
AAPG clinical trials: ASCENTAGE PHARMA GROUP INTERNATIONAL
Every trial on ClinicalTrials.gov where ASCENTAGE PHARMA GROUP INTERNATIONAL is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 59
- Trials linked
- 53
- As lead sponsor
- 6
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
AAPG on the catalyst calendar · AAPG registry changes
- Primary completion May 27, 2025ActualPhase 1NCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsAscentage Pharma Group Inc. · EGFR Positive Non-small Cell Lung CancerCompletedAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 1NCT07424833A Study of APG-3288 in Relapsed/Refractory Blood CancersAscentage Pharma Group Inc. · Relapsed/Refractory Hematological MalignanciesRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT06641414Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).Ascentage Pharma Group Inc. · Higher-risk Myelodysplastic SyndromeRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 3NCT06423911Study of Olverembatinib (HQP1351) in Patients With CML-CPAscentage Pharma Group Inc. · Chronic Myeloid LeukemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2027Sponsor estimatePhase 1/Phase 2NCT05701306APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsAscentage Pharma Group Inc. · NeuroblastomaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT06319456A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Ascentage Pharma Group Inc. · CLL/SLLRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc. · GISTRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT03917043APG-2449 in Patients With Advanced Solid TumorsAscentage Pharma Group Inc. · Advanced Solid CancerRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT06687070APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STAscentage Pharma Group Inc. · Platinum-resistant Recurrent Ovarian CancerRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT06104566Global Trial in APG2575 for Patients With CLL/SLLAscentage Pharma Group Inc. · CLL/SLLRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 1/Phase 2NCT04501120Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLAscentage Pharma Group Inc. · Relapsed/Refractory Acute Myeloid LeukaemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2024ActualPhase 1NCT03913949A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesAscentage Pharma Group Inc. · Chronic Lymphocytic LeukemiaActive, not recruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 3NCT06051409A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Ascentage Pharma Group Inc. · Ph+ ALLRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 1NCT05773586A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.Ascentage Pharma Group Inc. · AnemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT03594422A Study of HQP1351 in Patients With GIST or Other Solid TumorsAscentage Pharma Group Inc. · Gastrointestinal Stromal Tumor (GIST)RecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLAscentage Pharma Group Inc. · Chronic Lymphocytic LeukemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2024ActualPhase 1/Phase 2NCT04643405APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaAscentage Pharma Group Inc. · Advanced Pancreatic CancerTerminatedAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2024ActualPhase 1/Phase 2NCT04284488Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsAscentage Pharma Group Inc. · Advanced Solid TumorTerminatedAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2026Sponsor estimatePhase 1NCT07282093Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentAscentage Pharma Group Inc. · PharmacokineticRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2026Sponsor estimatePhase 1/Phase 2NCT06182969A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.Ascentage Pharma Group Inc. · SLERecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 25, 2028Sponsor estimatePhase 3NCT06389292A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaAscentage Pharma Group Inc. · Acute Myeloid LeukemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2029Sponsor estimatePhase 1NCT04260022Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc. · Leukemia, Myeloid, ChronicRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2026Sponsor estimatePhase 2NCT04496349A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLAscentage Pharma Group Inc. · T-Prolymphocytic LeukemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2024ActualPhase 1NCT04260217APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaAscentage Pharma Group Inc. · Waldenstrom MacroglobulinemiaCompletedAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2025Sponsor estimatePhase 1/Phase 2NCT03611868A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsAscentage Pharma Group Inc. · Unresectable or Metastatic Melanoma or Advanced Solid TumorsActive, not recruitingAAPGLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 34 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner